# CJC-1295 DAC + Ipamorelin

> Combination — not ranked · Combos · reviewed 2026-11-08
> Source page: https://peptidemeta.com/p/cjc-1295-dac-ipamorelin/

## Quick answers

**What is CJC-1295 DAC + Ipamorelin?**

One of the most popular GH secretagogue stacks, combining a long-acting GHRH analog with a selective GHRP for sustained, synergistic growth hormone elevation. CJC-1295 with DAC (long-acting GHRH analogue) plus ipamorelin (ghrelin-receptor agonist).

**What is in CJC-1295 DAC + Ipamorelin?**

CJC-1295 DAC + Ipamorelin typically combines CJC-1295 (with DAC) and Ipamorelin. Commercial products vary.

**How strong is the evidence for CJC-1295 DAC + Ipamorelin?**

It is not ranked. A PubMed search found no published studies of this combination; only reviews mention it. CJC-1295 (with DAC) and ipamorelin each have small human pharmacology studies.

**Is CJC-1295 DAC + Ipamorelin FDA-approved?**

No. CJC-1295 DAC + Ipamorelin is not an approved product; no regulator has reviewed the combination.

**Is CJC-1295 DAC + Ipamorelin banned in sport?**

Yes. CJC-1295 DAC + Ipamorelin is prohibited in sport by the World Anti-Doping Agency under S2 (peptide hormones, growth factors, related substances and mimetics).

**How does CJC-1295 DAC + Ipamorelin work?**

This blend exploits synergy between GHRH and GHRP pathways. CJC-1295 DAC activates the GHRH receptor via cAMP/PKA signaling for sustained GH release (half-life 6-8 days due to albumin binding), while ipamorelin activates the ghrelin receptor (GHS-R1a) via IP3/PKC.

**What is known about the safety of CJC-1295 DAC + Ipamorelin?**

Both components have individual clinical trial data. Common side effects: water retention, tingling, headache, flushing.

## Key facts

- **Evidence tier:** not ranked
- **FDA:** not approved
- **WADA:** prohibited (S2)
- **Peptide:** yes
- **Routes studied:** Subcutaneous, Intramuscular
- **Components:** CJC-1295 (with DAC), Ipamorelin

## Overview

One of the most popular GH secretagogue stacks, combining a long-acting GHRH analog with a selective GHRP for sustained, synergistic growth hormone elevation.

## Mechanism

This blend exploits synergy between GHRH and GHRP pathways. CJC-1295 DAC activates the GHRH receptor via cAMP/PKA signaling for sustained GH release (half-life 6-8 days due to albumin binding), while ipamorelin activates the ghrelin receptor (GHS-R1a) via IP3/PKC. Together they produce amplified GH pulses exceeding either component alone.

## Effects reported in research

_Reported outcomes, not promises; see the evidence tier._

- Sustained and amplified GH release
- Improved body composition and fat loss
- Enhanced deep sleep and recovery
- Increased IGF-1 levels

## Safety & unknowns

Both components have individual clinical trial data. Common side effects: water retention, tingling, headache, flushing. CJC-1295 DAC provides sustained GH elevation which may increase IGF-1 beyond physiological levels. Ipamorelin adds minimal cortisol/prolactin risk. Not FDA-approved as a combination.

## Studies

- Teichman SL, Neale A, Lawrence B, et al. (2006). *Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults*. Journal of Clinical Endocrinology and Metabolism. Clinical trial. https://pubmed.ncbi.nlm.nih.gov/16352683/
  Two randomized placebo-controlled ascending-dose trials of the CJC-1295 (DAC) component in healthy adults: a single injection raised GH 2- to 10-fold for 6 days or more and IGF-I for 9–11 days (half-life 5.8–8.1 days).
- Raun K, Hansen BS, Johansen NL, et al. (1998). *Ipamorelin, the first selective growth hormone secretagogue*. European Journal of Endocrinology. Preclinical. https://pubmed.ncbi.nlm.nih.gov/9849822/
  Rat and swine study on the ipamorelin component: it released GH as effectively as GHRP-6 but, unlike GHRP-6 and GHRP-2, did not raise ACTH or cortisol.

## Status sources

- [Teichman et al. 2006 — CJC-1295 in healthy adults](https://pubmed.ncbi.nlm.nih.gov/16352683/)
- [Gobburu et al. 1999 — ipamorelin PK/PD in human volunteers](https://pubmed.ncbi.nlm.nih.gov/10496658/)
- [WADA 2026 Prohibited List — S2.2.4 names CJC-1295 and ipamorelin](https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf)

---

Educational reference only — not medical advice. No dosing information is published. Tiers rate the strength of published evidence, not effectiveness or safety.